Cargando…

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease

Detalles Bibliográficos
Autores principales:	Mazzini, Guilherme S., Khoraki, Jad, Browning, Matthew G., Campos, Guilherme M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834452/ https://www.ncbi.nlm.nih.gov/pubmed/29500352 http://dx.doi.org/10.1038/s41419-018-0386-3

Ejemplares similares

Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19
por: Kristem, Leonardo, et al.
Publicado: (2021)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
por: Jin, Lihua, et al.
Publicado: (2015)

Fatty liver diseases, bile acids, and FXR
por: Zhu, Yan, et al.
Publicado: (2016)

The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles
por: Almeida, Maria Inês, et al.
Publicado: (2016)

Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA
por: Lee, Yo Han, et al.
Publicado: (2021)

Dietary Sodium and Nonalcoholic Fatty Liver Disease: A Systematic Review
por: da Silva Ferreira, Guilherme, et al.
Publicado: (2023)

Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling
por: Pan, Linyu, et al.
Publicado: (2023)

Roux en Y gastric bypass hypoglycemia resolves with gastric feeding or reversal: Confirming a non-pancreatic etiology
por: Davis, Dawn Belt, et al.
Publicado: (2018)

Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease
por: Shen, Nan, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Silibinin improves nonalcoholic fatty liver by regulating the expression of miR-122: An in vitro and in vivo study
por: Yang, Liying, et al.
Publicado: (2021)

Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway
por: Luo, Minmin, et al.
Publicado: (2021)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease
por: Auguet, Teresa, et al.
Publicado: (2016)

miR‐149 controls non‐alcoholic fatty liver by targeting FGF‐21
por: Xiao, Junjie, et al.
Publicado: (2016)

Retraction Statement: Inhibition of miR‐499‐5p expression improves nonalcoholic fatty liver disease
Publicado: (2020)

Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease
por: Irie, Makoto, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Kim, Tae Hyung, et al.
Publicado: (2021)

Visceral leishmaniasis in Brazil: rationale and concerns related to reservoir control
por: Werneck, Guilherme Loureiro
Publicado: (2014)

Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
por: Xu, Nan, et al.
Publicado: (2020)

High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease
por: Alhasson, Firas, et al.
Publicado: (2018)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

Exercise-Induced ADAR2 Protects against Nonalcoholic Fatty Liver Disease through miR-34a
por: Wang, Zhijing, et al.
Publicado: (2022)

Concurrent epidemics of dengue and COVID-19 in Peru: Which way forward?
por: Hasan, Mohammad Mehedi, et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Exosomal miR-19b-3p communicates tubular epithelial cells and M1 macrophage
por: Wang, Zhi-wei, et al.
Publicado: (2019)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
por: Correia, Jorge C., et al.
Publicado: (2015)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

MiR-103-3p promotes hepatic steatosis to aggravate nonalcoholic fatty liver disease by targeting of ACOX1
por: Ding, Jiexia, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know
por: Bikeyeva, Viktoriya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljhk7h0bmkdo4mdrihri0tbh6l